Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
28.58
-0.01 (-0.03%)
Nov 19, 2025, 11:31 AM EST - Market open
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Viridian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $39.6, which forecasts a 38.56% increase in the stock price over the next year. The lowest target is $26 and the highest is $61.
Price Target: $39.6 (+38.56%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 5 |
| Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +57.45% | Nov 6, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $61 | Strong Buy | Reiterates | $61 | +113.44% | Nov 4, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $32 → $36 | Buy | Maintains | $32 → $36 | +25.96% | Oct 21, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $27 → $30 | Strong Buy | Maintains | $27 → $30 | +4.97% | Aug 7, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $45 → $41 | Buy | Maintains | $45 → $41 | +43.46% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
129.98K
from 302.00K
Decreased by -56.96%
Revenue Next Year
49.09M
from 129.98K
Increased by 37,670.06%
EPS This Year
-4.48
from -3.07
EPS Next Year
-4.32
from -4.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 309,750 | 130.6M | |||
| Avg | 129,979 | 49.1M | |||
| Low | n/a | 14.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.6% | 100,393.5% | |||
| Avg | -57.0% | 37,670.1% | |||
| Low | - | 11,278.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.53 | -3.27 | |||
| Avg | -4.48 | -4.32 | |||
| Low | -4.87 | -5.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.